Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors
Latest Information Update: 04 Jul 2024
Price :
$35 *
At a glance
- Drugs NW 301D (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 04 Jul 2024 New trial record